Rosetta (ROSG), Complete Genome (GNOM) Shares Surge as Study Finds Genome Sequencing Could Give Early Hints to Disease (GENE)
Get Alerts ILMN Hot Sheet
Join SI Premium – FREE
Stocks in the genome group are on the move Thursday afternoon following a Bloomberg article which cites a recent study as suggesting genome screens on healthy people may offer key hints about their risks of cancer.
The data comes out of the US National Human Genome Research Institute and was released in the American Journal of Human Genetics earlier Thursday. The report specifically mentioned genome sequencing machines from Illumina (Nasdaq: ILMN) and Life Tech (Nasdaq: LIFE), suggesting such devices could be used to alert people to possible risks for disease very early on.
While Illumina and Life Tech shares are relatively calm since the Bloomberg report, shares of Complete Genomics (Nasdaq: GNOM), Rosetta Genomics (Nasdaq: ROSG) and Genetic Technologies (Nasdaq: GENE) are up 7.3 percent, 8.8 percent, and 16.5 percent, respectively.
The data comes out of the US National Human Genome Research Institute and was released in the American Journal of Human Genetics earlier Thursday. The report specifically mentioned genome sequencing machines from Illumina (Nasdaq: ILMN) and Life Tech (Nasdaq: LIFE), suggesting such devices could be used to alert people to possible risks for disease very early on.
While Illumina and Life Tech shares are relatively calm since the Bloomberg report, shares of Complete Genomics (Nasdaq: GNOM), Rosetta Genomics (Nasdaq: ROSG) and Genetic Technologies (Nasdaq: GENE) are up 7.3 percent, 8.8 percent, and 16.5 percent, respectively.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- AstraZeneca (AZN) shares jump on much stronger Q1 top and bottom line
- Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!